---
title: 'Leveraging Ligand Affinity and Properties: Discovery of Novel Benzamide-Type
  Cereblon Binders for the Design of PROTACs'
date: '2023-10-30'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37902300/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20231030180725&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: Immunomodulatory imide drugs (IMiDs) such as thalidomide, pomalidomide,
  and lenalidomide are the most common cereblon (CRBN) recruiters in proteolysis-targeting
  chimera (PROTAC) design. However, these CRBN ligands induce the degradation of IMiD
  neosubstrates and are inherently unstable, degrading hydrolytically under moderate
  conditions. In this work, we simultaneously optimized physiochemical properties,
  stability, on-target affinity, and off-target neosubstrate modulation features to
  ...
disable_comments: true
---
Immunomodulatory imide drugs (IMiDs) such as thalidomide, pomalidomide, and lenalidomide are the most common cereblon (CRBN) recruiters in proteolysis-targeting chimera (PROTAC) design. However, these CRBN ligands induce the degradation of IMiD neosubstrates and are inherently unstable, degrading hydrolytically under moderate conditions. In this work, we simultaneously optimized physiochemical properties, stability, on-target affinity, and off-target neosubstrate modulation features to ...